Ro 08-2750
CAS No. 37854-59-4
Ro 08-2750( —— )
Catalog No. M26808 CAS No. 37854-59-4
Ro 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC50 of ~ 1 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 65 | In Stock |
|
| 5MG | 59 | In Stock |
|
| 10MG | 92 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRo 08-2750
-
NoteResearch use only, not for human use.
-
Brief DescriptionRo 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC50 of ~ 1 μM.
-
DescriptionRo 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC50 of ~ 1 μM. Ro 08-2750 is a selective MSI RNA-binding activity inhibitor, with an IC50 of 2.7 μM. Ro 08-2750 inhibits NGF binding to p75NTR selectively over TRKA.(In Vitro):Ro 08-2750 inhibits the survival of human AML lines and patient cells. Ro 08-2750 suppresses MSI2 RNA-binding and alters the MSI2 gene signature. Ro 08-2750 binds to the NGF dimer thereby probably inducing a change in its conformation such that NGF cannot bind to p75NTR anymore. Ro 08-2750 (5-10 μM; 8 hours) increases differentiation and apoptosis in myeloid leukemia cells. Ro 08-2750 (10 nM) fully rescues cells from undergoing NGF-induced SK-N-MC 103 cell death .(In Vivo):In a myeloid leukemia model in vivo, Ro 08-2750 (13.75 mg/kg; i.p.) suppresses leukemogenesis .
-
In VitroRo 08-2750 binds to the NGF dimer thereby probably inducing a change in its conformation such that NGF cannot bind to p75NTR anymore.Ro 08-2750 (10 nM) completely rescues cells from undergoing NGF-induced SK-N-MC 103 cells death.Ro 08-2750 (5-10 μM; 8?hours) increases differentiation and apoptosis in myeloid leukemia cells.Ro 08-2750 inhibits survival of human AML lines and patient cells.Ro 08-2750 inhibits MSI2 RNA-binding and alters MSI2 gene signature. Apoptosis Analysis Cell Line:MLL-AF9?+?BM cells Concentration:5?μM, 10?μM Incubation Time:8?hours Result:Increased apoptosis.
-
In VivoRo 08-2750 (13.75mg/kg; i.p.) inhibits leukemogenesis in a myeloid leukemia model in vivo. Animal Model:C57BL/6 wild type mice (10-12-weeks-old), MLL-AF9 murine leukemia model Dosage:13.75?mg/kg Administration:Intraperitoneal injection, at days 1, 4, 7, 10, and 13 (one day on, two days off drug)Result:Inhibited c-MYC levels and reduced disease burden.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAhR| Androgen Receptor| Antifungal| Estrogen Receptor/ERR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number37854-59-4
-
Formula Weight270.248
-
Molecular FormulaC13H10N4O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 4 mg/mL (14.80 mM)
-
SMILESCc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Liu J, et al. Whole transcriptome analysis of Penicillium digitatum strains treatmented with prochloraz reveals their drug-resistant mechanisms. BMC Genomics. 2015 Oct 24;16:855.
molnova catalog
related products
-
3-(2-Glucosyloxy-4-m...
2-O-beta-d-Glucosyloxy-4-methoxybenzenepropanoic acid[3-(2-Glucosyloxy-4-methoxyphenyl)propanoic acid] exhibits glutathione S-transferase (GST) inhibitory and antifungal activities.
-
DAGLβ-IN-1
DAGLβ-IN-1 is a universal intermediate for designing DAGL tailored activity-based probes, and is an inhibitor of diacylglycerol lipase-β (DAGLβ).
-
MC1742
MC1742 is an inhibitor of class I histone deacetylases (HDACs; IC50s = 0.1, 0.11, 0.02, and 0.61 μM for HDAC1, -2, -3, and -8, respectively) and class IIb HDACs (IC50s = 7 and 40 nM for HDAC6 and HDAC10, respectively).
Cart
sales@molnova.com